- Home
- VERI vs IMMX Comparison
VERI vs IMMX Comparison
Compare VERI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERI | IMMX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.0M | 306.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VERI | IMMX |
|---|---|---|
| Price | $3.08 | $10.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $10.00 | ★ $16.33 |
| AVG Volume (30 Days) | ★ 1.4M | 690.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.36 | 14.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,637,000.00 | N/A |
| Revenue This Year | $20.56 | N/A |
| Revenue Next Year | $19.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $1.34 |
| 52 Week High | $9.42 | $9.47 |
Technical Indicators
Market Signals| Indicator | VERI | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 76.72 |
| Support Level | $2.61 | $1.96 |
| Resistance Level | $3.15 | N/A |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 85.59 | 100.00 |
Price Performance
Historical ComparisonAbout VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.